Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Department of Health and Human Services
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Later
Posted
12/06/2024
Closes
2027-07-02
Eligibility
Eligibility
For profit organizations other than small businessesCounty governmentsNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationPublic and State controlled institutions of higher educationSmall businessesState governmentsCity or township governmentsIndependent school districtsSpecial district governmentsPrivate institutions of higher educationPublic housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Native American tribal governments (Federally recognized)Others (see text field entitled "Additional Information on Eligibility" for clarification)
Program
Funding area
Health - HL
Opportunity #
RFA-TR-25-002
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov